WO2005017104A3 - Cancer-linked gene as target for chemotherapy - Google Patents

Cancer-linked gene as target for chemotherapy Download PDF

Info

Publication number
WO2005017104A3
WO2005017104A3 PCT/US2004/018738 US2004018738W WO2005017104A3 WO 2005017104 A3 WO2005017104 A3 WO 2005017104A3 US 2004018738 W US2004018738 W US 2004018738W WO 2005017104 A3 WO2005017104 A3 WO 2005017104A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
methods
target
disclosed
chemotherapy
Prior art date
Application number
PCT/US2004/018738
Other languages
French (fr)
Other versions
WO2005017104A2 (en
Inventor
Bernd Weigle
Reinhard Ebner
Andrea Kiessling
Original Assignee
Avalon Pharmaceuticals
Bernd Weigle
Reinhard Ebner
Andrea Kiessling
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avalon Pharmaceuticals, Bernd Weigle, Reinhard Ebner, Andrea Kiessling filed Critical Avalon Pharmaceuticals
Publication of WO2005017104A2 publication Critical patent/WO2005017104A2/en
Publication of WO2005017104A3 publication Critical patent/WO2005017104A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cancer-linked gene sequences, and derived amino acid sequences, are disclosed along with methods for assaying potential antitumor agents based on their modulation of the expression of these cancer-linked genes. Also disclosed are antibodies that react with the disclosed polypeptides and methods of using the antibodies to treat cancerous conditions, such as by using the antibody to target cancerous cells in vivo for purposes of delivering therapeutic agents thereto. Also described are methods of diagnosing using the gene sequences.
PCT/US2004/018738 2003-06-16 2004-06-10 Cancer-linked gene as target for chemotherapy WO2005017104A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47889403P 2003-06-16 2003-06-16
US60/478,894 2003-06-16

Publications (2)

Publication Number Publication Date
WO2005017104A2 WO2005017104A2 (en) 2005-02-24
WO2005017104A3 true WO2005017104A3 (en) 2006-07-06

Family

ID=34193027

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/018738 WO2005017104A2 (en) 2003-06-16 2004-06-10 Cancer-linked gene as target for chemotherapy

Country Status (1)

Country Link
WO (1) WO2005017104A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2177630A1 (en) * 2008-10-02 2010-04-21 Institut Gustave Roussy Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060860A2 (en) * 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes differentially expressed in human prostate cancer and their use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060860A2 (en) * 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes differentially expressed in human prostate cancer and their use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] 15 July 2002 (2002-07-15), NISHI ET AL., Database accession no. (AK096745) *
WEIGLE ET AL.: "D-PCA-2: A novel transcript highly overexpressed in Human prostate and prostate cancer", INT. J. CANCER, vol. 109, 2004, pages 882 - 892 *

Also Published As

Publication number Publication date
WO2005017104A2 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
WO2003097803A3 (en) Cancer-linked gene as target for chemotherapy
WO2003101400A3 (en) Cancer-linked gene as target for chemotherapy
WO2003105758A3 (en) Cancer-linked gene as target for chemotherapy
WO2003104399A3 (en) Cancer-linked gene as target for chemotherapy
WO2005047458A3 (en) Modified recombinant vaccina viruses and other microorganisms, uses thereof
WO2007113648A3 (en) Ctla4 antibody combination therapy
WO2007034221A3 (en) Non small cell lung cancer therapy prognosis and target
WO2005005601A8 (en) Compositions and methods for treating and diagnosing cancer
WO2003072125A8 (en) Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
MX2009013646A (en) Methods of diagnosing and treating cancer.
WO2005120588A3 (en) Peptides delivered to cell nuclei
WO2004031231A3 (en) Genes and polypeptides relating to prostate cancers
WO2003066663A3 (en) Peptides for recognition and targeting of glial cell tumors
WO2004078215A3 (en) Use of antibody conjugated deoxycytidine kinase for adept
WO2004037198A3 (en) Antibody-mediated induction of tumor cell death
WO2003076579A3 (en) Cancer-linked gene as target for chemotherapy
WO2004026238A8 (en) Immunotherapeutic compositions and methods for the treatment of moderately to well-differentiated cancers
WO2003104401A3 (en) Cancer-linked gene as target for chemotherapy
WO2003104438A3 (en) Cancer-linked gene as target for chemotherapy
WO2003097802A3 (en) Cancer-linked gene as target for chemotherapy
WO2002031198A3 (en) Cancer-linked genes as targets for chemotherapy
WO2005062788A3 (en) Prostate specific proteins expressed in cancer and methods of use thereof
WO2005019475A3 (en) Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc)
WO2003076587A3 (en) Cancer-linked gene as target for chemotherapy
WO2005079490A3 (en) Methods of therapy and diagnosis using targeting of cells that express steap2 polypeptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase